{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T06:09:53Z","timestamp":1744351793662,"version":"3.37.3"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The treatment of low\u2010tumour burden follicular lymphoma (<jats:styled-content style=\"fixed-case\">LTBFL<\/jats:styled-content>) remains a challenge. Rituximab\u2010based strategies may be improved by adding chemotherapy. This Lymphoma Study Association multicentre phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study assessed rituximab and bendamustine in 63 patients with untreated <jats:styled-content style=\"fixed-case\">LTBFL<\/jats:styled-content> who were aged over 60\u00a0years old and had a follicular lymphoma International Prognostic Index (<jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content>) score \u22652. Induction comprised 4 weekly cycles of rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously combined with 2 cycles of bendamustine 90\u00a0mg\/m<jats:sup>2<\/jats:sup> days 1\u20132 with a 28\u2010day interval, followed by twelve cycles of 375\u00a0mg\/m<jats:sup>2<\/jats:sup> rituximab maintenance therapy every 8\u00a0weeks. The primary endpoint was complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>)\/unconfirmed <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u), at 12\u00a0weeks. Median age was 67\u00b74\u00a0years and median <jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content> was 3. Ultimately, 18 patients (29%) had high tumour burden according to Groupe d'Etude des Lymphomes Folliculaires criteria. The 12\u2010week <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u rate was 54\u00b70% and the overall response rate was 93\u00b77%. Surprisingly, 3 patients died during maintenance (2 sepsis, 1 neoplasm). Progression\u2010free survival was 85\u00b74% at 24\u00a0months. In <jats:styled-content style=\"fixed-case\">LTBFL<\/jats:styled-content> patients with <jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content> \u22652, two cycles of rituximab and bendamustine result in a <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> rate of 54\u00b70%. However, the treatment\u2010related deaths observed do not allow this regimen to be recommended for <jats:styled-content style=\"fixed-case\">LTBFL<\/jats:styled-content> patients aged over 60\u00a0years.<\/jats:p><jats:p>EudraCT: 2010\u2010020757\u201014; ClinicalTrials.gov: NCT01313611.<\/jats:p>","DOI":"10.1111\/bjh.15513","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T03:11:04Z","timestamp":1534475464000},"page":"76-86","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Bendamustine and rituximab in elderly patients with low\u2010tumour burden follicular lymphoma. Results of the <scp>LYSA<\/scp> phase <scp>II BRIEF<\/scp> study"],"prefix":"10.1111","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"first","affiliation":[{"name":"Department of Haematology and Cell Therapy University Hospital Tours France"},{"name":"Clinical Investigation Centre INSERM U1415, University Hospital Tours France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Sonet","sequence":"additional","affiliation":[{"name":"Department of Haematology Mont\u2010Godinne University Universit\u00e9 Catholique de Louvain CHU UCL Namur Yvoir Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Department of Haematology Saint\u2010Louis Hospital AP\u2010HP Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Anglaret","sequence":"additional","affiliation":[{"name":"Department of Haematology Valence Hospital Valence France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4389-6164","authenticated-orcid":false,"given":"Kamel","family":"Laribi","sequence":"additional","affiliation":[{"name":"Department of Haematology Le Mans Hospital Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Fruchart","sequence":"additional","affiliation":[{"name":"Department of Haematology Centre Francois Baclesse Caen France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"Department of Haematology Centre Henri Becquerel Rouen France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Araujo","sequence":"additional","affiliation":[{"name":"Department of Haematology Bayonne Hospital Bayonne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[{"name":"Department of Haematology Institut Bergoni\u00e9 Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Haematology Ren\u00e9 Dubos Hospital Pontoise France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Morineau","sequence":"additional","affiliation":[{"name":"Department of Haematology Catherine de Sienne Centre Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Nicolas\u2010Virelizier","sequence":"additional","affiliation":[{"name":"Department of Haematology Francois Magendie Centre Pessac France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[{"name":"Department of Haematology L\u00e9on B\u00e9rard Centre Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Haematology Ch\u00e2lon Hospital Ch\u00e2lon\u2010sur\u2010Sa\u00f4ne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9da","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Department of Haematology Paoli\u2010Calmettes Institute Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Orfeuvre","sequence":"additional","affiliation":[{"name":"Department of Haematology Bourg\u2010en\u2010Bresse Hospital Bourg\u2010en\u2010Bresse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Fahri","sequence":"additional","affiliation":[{"name":"Department of Haematology Angers University Hospital Angers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Couturier","sequence":"additional","affiliation":[{"name":"Lysa Pathology Department Mondor University Hospital Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Xerri","sequence":"additional","affiliation":[{"name":"Lysa Imaging Department Mondor University Hospital Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Feugier","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospital, and INSERM U954 Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Lymphoma Study Association (LYSA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_9_2_1","DOI":"10.1016\/S0140-6736(03)14110-4"},{"doi-asserted-by":"publisher","key":"e_1_2_9_3_1","DOI":"10.1016\/S1470-2045(14)70027-0"},{"doi-asserted-by":"publisher","key":"e_1_2_9_4_1","DOI":"10.1200\/JCO.1997.15.3.1110"},{"doi-asserted-by":"publisher","key":"e_1_2_9_5_1","DOI":"10.3324\/haematol.2014.117473"},{"doi-asserted-by":"publisher","key":"e_1_2_9_6_1","DOI":"10.1200\/JCO.1999.17.4.1244"},{"doi-asserted-by":"publisher","key":"e_1_2_9_7_1","DOI":"10.1200\/JCO.2006.09.2403"},{"doi-asserted-by":"publisher","key":"e_1_2_9_8_1","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low\u2010tumor burden follicular lymphoma (FL): survival analyses with extended follow\u2010up (F\/Up) of 7\u00a0years","volume":"108","author":"Colombat P.","year":"2006","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_10_1","DOI":"10.1093\/annonc\/mds177"},{"doi-asserted-by":"publisher","key":"e_1_2_9_11_1","DOI":"10.1111\/bjh.12915"},{"key":"e_1_2_9_12_1","first-page":"482","article-title":"A 3\u2010arm randomized phase II trial with bendamustine\/rituximab therapy in untreated high risk (HR) follicular lymphoma (FL): bortezomib induction or novel IMiD\u00ae continuation (BIONIC) study from the ECOG\u2010ACRIN Cancer Research Group","volume":"130","author":"Evens A.M.","year":"2017","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_13_1","DOI":"10.1182\/blood-2013-11-531327"},{"doi-asserted-by":"publisher","key":"e_1_2_9_14_1","DOI":"10.1016\/S1470-2045(14)70455-3"},{"doi-asserted-by":"publisher","key":"e_1_2_9_15_1","DOI":"10.1056\/NEJMoa1314583"},{"doi-asserted-by":"publisher","key":"e_1_2_9_16_1","DOI":"10.1056\/NEJM198412063112303"},{"doi-asserted-by":"publisher","key":"e_1_2_9_17_1","DOI":"10.1200\/JCO.2014.56.5853"},{"doi-asserted-by":"publisher","key":"e_1_2_9_18_1","DOI":"10.1200\/JCO.2014.59.9258"},{"key":"e_1_2_9_19_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V128.22.6.6","article-title":"Obinutuzumab\u2010based induction and maintenance prolongs progression\u2010free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the randomized Phase III GALLIUM study","volume":"128","author":"Marcus R.","year":"2016","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_9_20_1","DOI":"10.3324\/haematol.2010.037390"},{"doi-asserted-by":"publisher","key":"e_1_2_9_21_1","DOI":"10.1111\/bjh.13487"},{"doi-asserted-by":"publisher","key":"e_1_2_9_22_1","DOI":"10.1200\/JCO.2005.08.100"},{"doi-asserted-by":"publisher","key":"e_1_2_9_23_1","DOI":"10.1016\/S0140-6736(12)61763-2"},{"doi-asserted-by":"publisher","key":"e_1_2_9_24_1","DOI":"10.1200\/JCO.2012.46.9718"},{"doi-asserted-by":"publisher","key":"e_1_2_9_25_1","DOI":"10.1200\/JCO.1998.16.7.2332"},{"doi-asserted-by":"publisher","key":"e_1_2_9_26_1","DOI":"10.1182\/blood-2003-12-4434"},{"doi-asserted-by":"publisher","key":"e_1_2_9_27_1","DOI":"10.1200\/JCO.2010.33.4474"},{"volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow S.H.","key":"e_1_2_9_28_1"},{"doi-asserted-by":"publisher","key":"e_1_2_9_29_1","DOI":"10.1016\/S1470-2045(13)70551-5"},{"doi-asserted-by":"publisher","key":"e_1_2_9_30_1","DOI":"10.1200\/JCO.2005.12.052"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T07:39:59Z","timestamp":1694849999000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/bjh.15513"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15513","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"2018-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}